Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials

Autor: Ruiz-Schutz, Viviane C., Gomes, Larissa M., Mariano, Rodrigo C., de Almeida, Daniel V.P., Pimenta, Juliana M., Dal Molin, Graziela Z., Kater, Fabio R., Yamamura, Rosely, Correa Neto, Nelson F., Maluf, Fernando C., Schutz, Fabio A.

Publikováno v: In Critical Reviews in Oncology / Hematology September 2019 141:163-173

Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors.

Autor: Zibetti Dal Molin G; Medical Oncology, Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Brazil., Westin SN; Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Msaouel P; Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gomes LM; Medical Oncology, Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Brazil., Dickens A; Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Coleman RL; Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA rcoleman@mdanderson.org.

Publikováno v: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2020 Jan; Vol. 30 (1), pp. 89-93. Date of Electronic Publication: 2019 Dec 01.